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Abstract
High levels of the anti-apoptotic BCL-2 family member MCL-1 are frequently found in breast cancer and, appropriately,
BH3-mimetic drugs that specifically target MCL-1’s function in apoptosis are in development as anti-cancer therapy. MCL-1
also has reported non-canonical roles that may be relevant in its tumour-promoting effect. Here we investigate the role of
MCL-1 in clinically relevant breast cancer models and address whether the canonical role of MCL-1 in apoptosis, which can
be targeted using BH3-mimetic drugs, is the major function for MCL-1 in breast cancer. We show that MCL-1 is essential in
established tumours with genetic deletion inducing tumour regression and inhibition with the MCL-1-specific BH3-mimetic
drug S63845 significantly impeding tumour growth. Importantly, we found that the anti-tumour functions achieved by MCL-1
deletion or inhibition were completely dependent on pro-apoptotic BAX/BAK. Interestingly, we find that MCL-1 is also
critical for stem cell activity in human breast cancer cells and high MCL1 expression correlates with stemness markers in
tumours. This strongly supports the idea that the key function of MCL-1 in breast cancer is through its anti-apoptotic function.
This has important implications for the future use of MCL-1-specific BH3-mimetic drugs in breast cancer treatment.
Introduction
The BCL-2 family regulates mitochondrial integrity to ensure
appropriate activation of programmed cell death (CD) in
response to developmental or physiological cues. This is
achieved through balanced protein:protein interactions
between pro- and anti-apoptotic family members that regulate
the activation of BAX/BAK. Active BAX and BAK per-
meabilise the mitochondrial outer membrane leading to the
release of mitochondrial intermembrane space proteins that
trigger caspase activation and CD [1]. Evasion of CD is
considered a hallmark of cancer, and apoptosis represents a
major barrier to cellular transformation and oncogenic pro-
gression [2]. Resistance to apoptosis in cancer can be
achieved through disruption in the balance of BCL-2 proteins
to enhance pro-survival functions. The paradigm for this is
aberrant BCL-2 expression through chromosomal transloca-
tion in follicular lymphoma though increased anti-apoptotic
BCL-2 protein expression occurs across diverse cancer types
through mechanisms including gene amplification, increased
transcription or translation and protein stability [3, 4].
Apoptotic sensitivity can be restored by chemical mimicry of
the pro-apoptotic BCL-2 proteins with so-called BH3-
mimetic drugs. Neutralisation of elevated pro-survival BCL-2
family members has demonstrable clinical impact in cancer;
venetoclax (ABT199) is a BCL-2-specific BH3-mimetic that
has single-agent and combinatorial efficacy in some types of
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lymphoma and BH3-mimetic drugs are now in clinical trials
for a range of cancers [5–8].
BH3-mimetic drugs that specifically target MCL-1 have
been developed and entered clinical trials for the treatment
of haematopoietic malignancies. In addition to its prominent
role in haematopoietic cancers, MCL-1 has emerged as a
key player in breast cancer with high levels of MCL-1
protein in primary breast cancer samples correlating with
poor patient prognosis [9–16]. There are compelling data
showing that targeting MCL-1 represents a therapeutic
opportunity in breast cancer with model systems revealing
that breast cancer may be dependent on MCL-1, and that
MCL-1 inhibition can enhance the effect of conventional
cancer therapies [9–12, 16–19]. Importantly, numerous non-
apoptotic roles for MCL-1 have also been described that
may also be relevant to cancer. These include regulation of
mitochondrial dynamics, oxidative phosphorylation, reac-
tive oxygen species, autophagy, pluripotency, long chain
fatty acid synthesis and the DNA damage response [20–28].
Importantly, not all of these functions can be blocked by
BH3-mimetic drugs implying that additional approaches to
target MCL-1 may be required for maximal therapeutic
impact (reviewed in [29]). Addressing this key point, we set
out to determine whether fully established tumours in an
immune competent breast cancer model were dependent on
MCL-1 and, if so, whether this was due to anti-apoptotic
MCL-1 activity and/or its non-apoptotic functions.
We find that acute genetic deletion or pharmaceutical
targeting of MCL-1 significantly impedes the growth of
established MMTV-PyMT mammary tumours in vivo.
Crucially, this oncogenic function of MCL-1 was com-
pletely dependent upon its anti-apoptotic function because
loss of pro-apoptotic BAX and BAK completely prevented
the effect of MCL-1 loss. Importantly, MCL-1 was
required for breast cancer stem cell function in vitro and
this was also due to MCL-1’s canonical anti-apoptotic
function since it could be ablated by deletion of BAX/BAK
and targeted with MCL-1-specific BH3-mimetic drugs.
These data strongly support the premise of MCL-1 inhi-
bition as an adjunct to breast cancer therapy and highlight
that the major role of MCL-1 in breast cancer is via inhi-
bition of apoptosis.
Results
MCL-1 is required for tumour maintenance in vivo
Having previously demonstrated an essential genetic
requirement for MCL-1 in tumour development in the
MMTV-PyMT mammary model we wanted to mimic ther-
apeutic targeting of MCL-1 in an adjuvant setting by
determining the impact of Mcl1 deletion in established
tumours [16]. MMTV-PyMT mice were crossed with
RosaCRE-ERT2;Mcl1fl/+ mice and cohorts aged until mam-
mary tumours reached 5 mm diameter at which time ubi-
quitous deletion of one allele of Mcl1 was achieved by
tamoxifen administration and tumour growth monitored
until clinical endpoint (Fig. 1A). Interestingly, inactivation
of just one allele of Mcl1 in these mice (denoted HET), at a
time when palpable tumours had already established, was
sufficient to restrict tumour growth and significantly extend
survival (Fig. 1B). Importantly, the total tumour burden for
mice wild type (WT) and HET for Mcl1 was comparable at
endpoint despite HET mice surviving significantly longer
(Fig. 1C and Supplementary Fig. 1A). Having shown that
acute deletion of just one allele of Mcl1 impedes the growth
of established tumours in vivo we investigated the impact of
targeting both alleles of Mcl1. To circumvent lethality due
to the requirement for MCL-1 in haematopoietic stem cells
and cardiomyocytes, we used a tumour fragment trans-
plantation system where MMTV-PyMT tumours harbouring
either WT or floxed alleles of Mcl1 are transplanted into
syngeneic recipients prior to tamoxifen-activated CRE-ERT2
recombination (Fig. 1D) [22, 23, 30]. In this way, fragments
of WT and Mcl1fl/fl (MCL-1 proficient) tumours were
engrafted into the mammary fat pad of multiple WT reci-
pients and allowed to establish before tamoxifen induction
to delete both alleles of Mcl1 in Mcl1fl/fl tumours.
Remarkably, homozygous Mcl1 deletion induced tumour
regression in 8/9 Mcl1fl/fl tumours but no WT tumour
regressed (Fig. 1E). This tumour-repressive effect of Mcl1
deletion was sustained and median survival increased from
47 to 91 days (P= 0.0022) relative to WT controls with 4/9
recipients of Mcl1fl/fl tumours surviving long term with no
palpable tumour remaining (Fig. 1F). In contrast, tumour
growth and survival of WT and Mcl1fl/fl tumours was
similar in the absence of active CRE (Supplementary
Fig. 1B, C). Together these results reveal that MCL-1 is an
essential gene in established tumours and that targeting
MCL-1 at clinically actionable stages of tumour develop-
ment can result in tumour regression with long-term impact
on survival.
MCL-1 inhibition significantly impedes growth of
MMTV-PyMT tumours in vivo
Our genetic models of acute Mcl1 deletion provide strong
rationale for MCL-1 as a therapeutic target in established
breast cancers. Recent pharmaceutical advances have led to
the development of BH3-mimetic MCL-1 inhibitors suitable
for in vivo use [17, 31–33]. We therefore wished to further
model targeting MCL-1 in a breast cancer therapy setting
and test whether inhibition of MCL-1 with a BH3-mimetic
drug would impact on clinically palpable mammary
tumours. To this end, we used a syngeneic orthotopic
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Fig. 1 MCL-1 is required for MMTV-PyMT tumour maintenance
in vivo. A Diagram of experimental set-up for results presented in B, C.
Female MMTV-PyMT mice were monitored until the largest tumour
reached 5mm diameter, induced with tamoxifen (day 0 on graph) for
4 consecutive days (to induce recombination in mice carrying RosaCRE-
ERT2;Mcl1fl/+ alleles) and monitored until clinical endpoint.
B Kaplan–Meier survival graph of mice WT for Mcl1 (n= 9) (median
survival 18 days) and HET (n= 7) (median survival 23 days) post
tamoxifen induction (P= 0.0424). Log-rank (Mantel–Cox) test. Geno-
types of WT mice were 2× MMTV-PyMT;RosaCRE-ERT2;Mcl1+/+;
RosaLSL-RFP, 4×MMTV-PyMT;Mcl1fl/+;RosaLSL-RFP and 3×MMTV-PyMT;
Mcl1fl/fl;RosaLSL-RFP, genotypes of seven HET mice were MMTV-PyMT;
RosaCRE-ERT2;Mcl1fl/+;RosaLSL-RFP. C Total tumour weight at endpoint
of mice shown in B. WT (n= 9), HET (n= 7), n.s. not significant,
unpaired t test. D Diagram of experimental set-up for results presented in
E, F (see also Supplementary Fig. 1). Tumours were harvested from
three ‘Mcl1WT’ (genotypes were MMTV-PyMT;RosaCRE-ERT2;Mcl1+/+;
RosaLSL-RFP/MMTV-PyMT;Mcl1fl/+;RosaLSL-RFP/MMTV-PyMT;Mcl1fl/fl;
RosaLSL-RFP) and 3 ‘Mcl1fl/fl’ (genotypes were 2×MMTV-PyMT;RosaCRE-
ERT2;Mcl1fl/fl;RosaLSL-RFP and 1× MMTV-PyMT;RosaCRE-ERT2;Mcl1fl/fl)
donor mice and tumour fragments orthotopically transplanted into multiple
FVB recipients (ten recipients of Mcl1WT fragments and nine recipients of
Mcl1fl/fl fragments). Transplanted tumours were monitored until ~5mm
diameter before tamoxifen-induced CRE-ERT2 activation. E Change in
tumour volume 3 weeks post Mcl1 deletion. Error bars represent mean ±
SD, ***P= 0.0009 unpaired t test. Red dotted line indicates 100% of
starting volume (i.e., no change). No Mcl1WT tumours regressed and 8/9
Mcl1fl/fl tumours regressed following CRE activation. F Kaplan–Meier
survival curve of mice carrying tumours shown in (E). Median survival
Mcl1WT 47 days, Mcl1fl/fl 91 days post tamoxifen induction P= 0.0022
Log-rank (Mantel–Cox) test.
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transplantation model (Fig. 2A, MMTV-PyMT;CRISPR/
Cas9 control cells described in Supplementary Fig. 2A).
When tumours reached 5 mm diameter, recipient mice were
randomly assigned to vehicle or MCL-1 inhibitor (S63845)
groups and underwent twice weekly treatment for 3 weeks.
MCL-1 inhibition with S63845 led to a significant impair-
ment of tumour growth (Fig. 2B and Supplementary
Fig. 2B) with reduction in post-treatment tumour weight to
around one third when compared to vehicle treated controls
(mean of 636 mg down to 184 mg, P= 0.0112, Fig. 2C).
Interestingly, once weekly treatment with 25 mg/kg S63845
with or without the conventional chemotherapeutic dox-
etaxel did not restrict expansion of MMTV-PyMT tumour
cells in vivo. This suggests that prolonged inhibition of
MCL-1 is required for a therapeutic effect and cannot be
significantly substituted by conventional chemotherapy in
this setting (Supplementary Fig. 2C, D). Thus, at appro-
priate dosing regimens, pharmaceutical targeting of MCL-1
with BH3-mimetics such as S63845 can act as a single-
agent therapy to slow tumour growth in a syngeneic mouse
model of breast cancer.
Breast cancer dependency on MCL-1 is lost in the
absence of BAX and BAK
Non-apoptotic functions for MCL-1 have been described in
cardiomyocytes, pluripotent stem cells, breast cancer stem cells
and neurons [13, 21–23, 26–28]. To determine whether the
conventional anti-apoptotic role of MCL-1 was responsible for
mammary tumour sensitivity to MCL-1 loss/inhibition we
deleted Bax and Bak to bypass the canonical anti-apoptotic
function of MCL-1 (regulation of mitochondrial outer mem-
brane permeabilization). Following orthologous transplant of
Bax/Bak CRISPR/Cas9 edited MMTV-PyMT cells into WT
recipients, tumours were allowed to grow to 5mm diameter
before treatment with MCL-1 inhibitor S63845 or vehicle
control (Fig. 3A and Supplementary Figs. 2A and 3A). Strik-
ingly, in tumours that had been engineered for BAX/BAK
deficiency, S63845 treatment had no impact on tumour growth
(Fig. 3B). This is in contrast to the pronounced impact of
S63845 we observed in the paired BAX/BAK-proficient
MMTV-PyMT cells (Fig. 2B, C and Supplementary Fig. 2A).
Whilst we had shown thatMcl1 deletion can result in long-term
Fig. 2 MCL-1 inhibition restricts growth of established MMTV-
PyMT tumours in vivo. A Diagram of experimental set-up for results
presented in B, C. MMTV-PyMT cell line (CRISPR/Cas9 control,
described in Supplementary Fig. 2) was injected into mammary fat pad
of FVB recipients and tumours were allowed to grow to ~5 mm before
assignment to vehicle or S63845 treatment groups. S63845 treatment
was at 25 mg/kg IV twice per week for 3 weeks and tumour volume
monitored. B Tumour growth is suppressed upon treatment with
S63845, individual tumours were measured thrice weekly and points
represent weekly mean ± SE. Vehicle control (n= 7) mice and S63845
(n= 10) mice. C Tumour weight at end of experiment following
3 weeks of vehicle (n= 7) or S63845 treatment (n= 10). Graph shows
mean ± SD, unpaired t test. *P= 0.0112.
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tumour suppression (Fig. 1F), genetic deletion of Mcl1 had no
effect on tumour growth in BAX/BAK-deficient tumours
(Fig. 3C–E) and unlike BAX/BAK-proficient MMTV-PyMT
tumours, decreased MCL-1 expression was still apparent in the
context of BAX/BAK loss (Fig. 3F and Supplementary
Fig. 3B–D) [16].
MCL-1 is essential for MMTV-PyMT cancer stem cell
viability
Previous studies have grouped human breast cancer cell
lines into MCL-1-dependent and MCL-1-independent
groups based on in vitro sensitivity to MCL-1 inhibition
Fig. 3 MCL-1 dependence requires BAX/BAK. A Diagram of
experimental set-up for results presented in B. MMTV-PyMT CRISPR/
Cas9 Bax/Bak cell line (derivation described in Supplementary
Fig. 2A) was injected into mammary fat pad of FVB recipients and
tumours allowed to grow to ~5 mm before assignment to vehicle or
S63845 treatment groups. S63845 treatment was at 25 mg/kg IV twice
per week for 3 weeks. B Mean tumour weight of mice described in A,
following 3 weeks of vehicle control (n= 7) or S63845 (n= 7)
treatment (25 mg/kg IV twice per week) is shown (±SD), n.s. not
significant unpaired t test. C Diagram of experimental set-up for results
presented in D–F. MMTV-PyMT; CRISPR/Cas9 Bax/Bak tumour cell
line (as used in A, B, this cell line carries RosaCRE-ERT2;Mcl1fl/fl
alleles that were not activated in A, B, derivation described in Sup-
plementary Fig. 2A) was injected into mammary fat pad of FVB
recipients and tumours allowed to grow to ~5 mm before assignment to
vehicle or tamoxifen groups (tamoxifen induces CRE-ERT2-mediated
deletion of Mcl1fl/fl); therefore, vehicle treated tumours will be MCL-1
proficient and tamoxifen-induced tumours (TAM) will be MCL-1
deficient. Tumour size was monitored by calliper measurement thrice
weekly until harvesting at predefined ethical endpoint (15 mm dia-
meter). D Points indicate individual tumour weights at endpoint,
vehicle control (n= 5) or tamoxifen (n= 5). Error bars represent
mean ± SD, n.s. not significant unpaired t test. E Kaplan–Meier graph
showing tumour-related survival of mice shown in D. Day 0 indicates
vehicle/tamoxifen induction (at tumour diameter ~5 mm). Mcl1 dele-
tion in established tumours does not alter survival when Bax/Bak have
been CRISPR/Cas9 targeted. Vehicle control (n= 5) or tamoxifen
(n= 5). P= 0.2482 Log-rank (Mantel–Cox) test. F Western blot
quantification shows sustained decrease in MCL-1 from endpoint
tumours shown in D, E. Tumour material sampled for western blot will
include host-derived (WT for Mcl1) stroma and donor-derived tumour
epithelium. MCL-1 expression is calculated relative to β-actin control
for each sample, each point represents an individual tumour and error
bars represent mean ± SD. **P < 0.01, unpaired t test. Western blots
shown in Supplementary Fig. 3B.
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or knockdown in 2D monolayer assays [9, 12, 34]. To our
surprise, the dramatic impact of loss or inhibition of MCL-1
in MMTV-PyMT tumours that we observed in vivo was not
recapitulated in vitro with acute deletion of MCL-1 in cell
lines derived from MMTV-PyMT primary tumours (here-
after referred to as tumour cell lines) (Fig. 4A, B and
Supplementary Fig. 4A). Moreover, treatment with the
MCL-1-specific BH3-mimetic drug S63845 alone failed to
overtly affect viability when tumour cell lines were main-
tained in 2D monolayers (Fig. 4B and Supplementary
Fig. 4A). In 2D culture these tumour cell lines are however
still dependent on pro-survival BCL-2 proteins as combined
targeting of MCL-1 (genetically or pharmaceutically with
S63845) and BCL-2/BCL-XL (with ABT737) resulted in
high, but variable, levels of CD (Fig. 4B, also observed in
an additional independently derived tumour cell line in
Fig. 4 MCL-1 is essential for MMTV-PyMT breast cancer stem
cells. A Western blot showing impact of CRE activation on MCL-1
and BCL-XL expression in a cell line from MMTV-PyMT;RosaCRE-
ERT2;Mcl1fl/fl tumour. CRE activated in vitro with 100 nM 4-
hydroxytamoxifen (4-OHT), samples harvested after 72 h. MCL-1 is
efficiently deleted, BCL-XL level is not increased. B Genetic deletion
or pharmacological inhibition of MCL-1 does not inhibit tumour cell
line viability in 2D culture. Mcl1 deletion induced with 100 nM 4-
OHT at time of plating, medium changed 24 h later and 1 μM of
indicted BH3-mimetic drugs added for an additional 24 h before
quantification of cell death as expressed by Sytox/Confluence. Cells
plated in triplicate wells and repeated three times. Graph shows
mean ± SD, no significant differences as determined by one-way
ANOVA with Tukey’s correction for multiple comparisons. Cell
line derived from MMTV-PyMT;RosaCRE-ERT2;Mcl1fl/fl tumour.
C MMTV-PyMT cell lines show co-dependence on MCL-1 and BCL-
XL in 2D culture. Induction of Mcl1 deletion with 100 nM 4-OHT at
time of plating, medium changed 24 h later and 1 μM of indicted BH3-
mimetic drugs added for a further 24 h prior to determining viability by
Sytox/Confluence. Cells plated in triplicate, for three experiments, data
points represent mean of individual experiments (two independent cell
lines from MMTV-PyMT;RosaCRE-ERT2;Mcl1fl/fl tumours contributed
to these data points (lines 3.1j and 5.1e with 5.1e being tested twice).
Graph shows mean ± SD, **P < 0.01 determined by one-way ANOVA
with Tukey’s correction for multiple comparisons. D MCL-1 deletion
or inhibition impairs cancer stem cell activity. MMTV-PyMT cell lines
were plated as single-cell suspensions in a tumoursphere assay and
inducer/inhibitor (4-OHT or A1210477) added at time of plating.
CRE-ERT2 was activated in vitro with 100 nM 4-OHT (‘CRE activa-
tion’) to delete Mcl1 in Mcl1fl/fl, cells or MCL-1 inhibited with 1 µM
A1210477 at time of plating. Tumoursphere count on day 7 is
expressed as percentage relative to untreated control. Points represent
mean tumoursphere count relative to control condition for each cell
line. WT tumour cell line (3.3 h) is MMTV-PyMT;RosaCRE-ERT2;
Mcl1+/+, experiment was set up a total of four independent times with
4-OHT and A1210477 treatment carried out on three of those repeats.
Mcl1fl/fl data points come from two independent MMTV-PyMT;
RosaCRE-ERT2;Mcl1fl/fl tumour cell lines, line 3.1j was set up with 4-
OHT five independent times and A1210477 treatment carried out on
three of those repeats and line 5.1e was set up four independent times
with 4-OHT and A1210477 treatment carried out two repeats. Graph
shows mean ± SE. **P < 0.01, ****P < 0.0001, one-way ANOVA
analysis with Tukey’s correction for multiple comparisons.
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Supplementary Fig. 4A). Parsing of the relative contribution
of BCL-2 and BCL-XL with additional BH3-mimetic drugs
ABT199 (BCL-2 specific) and WEHI536 (BCL-XL spe-
cific) revealed that together with MCL-1, BCL-XL (rather
than BCL-2) is required for tumour cell line monolayer
viability and this is not due to compensatory upregulation of
BCL-XL in the absence of MCL-1 (Fig. 4A, C).
In contrast to the indifference of these tumour cell lines
to MCL-1 deletion or inhibition in 2D adherent culture,
there was a strong effect in 3D-tumoursphere culture. An
important role for MCL-1 in breast cancer stem cells has
been suggested and we reasoned that the bulk of cells
growing in vitro in monolayers might not represent the cells
driving tumour maintenance in vivo such as cancer stem
cells [13]. To address this, a tumoursphere assay in non-
adherent culture was utilised that is known to reflect breast
cancer stem cell activity [35]. This revealed a strong genetic
requirement for MCL-1 in breast cancer stem cells
(Fig. 4D), which was pharmacologically confirmed using
the MCL-1-specific BH3-mimetic drug A1210477
(Fig. 4D). Therefore, whilst MCL-1 may be dispensable for
bulk MMTV-PyMT cell culture in 2D monolayer, it is
essential for growth of breast cancer stem cells in vitro.
MCL-1 is required for human breast cancer stemness
via BAX/BAK
Given the profound requirement for MCL-1 in tumours and
cancer stem cells in the mouse MMTV-PyMT model, we
wished to interrogate the relevance of these findings to
human breast cancer. The MDA-MB-231 human triple-
negative breast cancer cell line shows properties of breast
cancer stem cells but in 2D monolayer is insensitive to loss
or inhibition of MCL-1 [9, 12, 34]. Intriguingly, we found
that in tumoursphere assay conditions MDA-MB-231 cells
were highly sensitive to MCL-1 inhibition with BH3-
mimetic drugs A1210477 and S63845 (Supplementary
Fig. 5A). To further test the requirement for canonical
MCL-1 function in human breast cancer stem cells we
therefore used CRISPR/Cas9 editing to generate MCL1-,
BAX/BAK- and MCL1/BAX/BAK-deficient versions of the
human breast adenocarcinoma MDA-MB-231 cell line
(Supplementary Fig. 5B). As expected, genetic targeting of
MCL-1 was tolerated without impacting on viability when
these cell lines were maintained in 2D culture ([9, 12, 34]
and data not shown). MDA-MB-231 control cells were
highly sensitive to MCL-1 inhibition with S63845 in the
tumoursphere assay and MCL1-deficient cells were unable
to form tumourspheres in vitro confirming a specific role for
MCL-1 in breast cancer stem cell function (Fig. 5A).
Importantly, this was completely restored upon co-deletion
of BAX/BAK (Fig. 5A). The ability of MCL-1 inhibitor
S63845 to restrict human breast cancer stem cell growth
was also negated in the absence of BAX/BAK, clearly
illustrating the importance of canonical anti-apoptotic
MCL-1 function in breast cancer stem cells (Fig. 5A).
Together with our experiments utilising mouse models,
these data reveal that MCL-1 function in breast cancer stem
cells in vitro and in tumour survival in vivo is due to its
anti-apoptotic function that is targetable by BH3-mimetic
drugs.
In order to probe whether MCL-1 might be specifically
associated with breast cancer stemness across human breast
cancers we examined a number of tumour gene expression
datasets. Importantly, MCL-1 expression was found to be
significantly correlated with stemness markers SNAI2, VIM,
CDH3, CD44 and ALDH1A1 (Fig. 5B and Supplementary
Fig. 5C, E, F). Splitting tumours into MCL1-low and
MCL1-high groups confirmed that these stemness markers
have elevated expression in MCL1-high tumours, which
were also significantly enriched for ER-negative tumours
(Fig. 5C and Supplementary Fig. 5D). Similar results were
also found for three other datasets, representing a combined
total of over 9000 breast tumours (Supplementary
Fig. 5C–F). Together, these data suggest that MCL-1 may
be an important player in maintaining stem cell populations
of primary breast cancers.
Discussion
In this study we provide evidence that targeting MCL-1
could have therapeutic impact in established breast cancers
and show that the mechanism of breast cancer dependence
on MCL-1 is through its canonical anti-apoptotic function
that can be targeted by MCL-1-specific BH3-mimetics.
MCL-1 inhibitors are in clinical development with a
focus on haematopoietic cancers including multiple mye-
loma and acute myeloid leukemia [36]. Using genetic
methods, we have previously shown that MCL-1 is required
for tumour development in a mouse model of breast cancer
and a number of groups have shown the importance of
MCL-1 for breast cancer cell line survival in vitro through
genetic and pharmaceutical targeting [9–12]. Despite these
encouraging findings, pharmaceutical targeting of MCL-1
as a single agent has proved inefficient at restricting breast
cancer growth in vivo when investigated with xenograft and
PDX models in immunodeficient mice [18, 19]. MCL-1 is
known to play essential roles in a number of haematopoietic
cell types [37]. Moreover, MCL-1-specific BH3-mimetic
drugs can have higher affinity for human versus mouse
MCL-1 meaning that xenograft studies may show efficient
BH3-mimetic engagement of MCL-1 in the human-derived
tumour at a given dose, whilst insufficiently targeting MCL-
1 within the tumour microenvironment. Anti-tumour effects
of MCL-1 inhibition could also occur through pro-tumour
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immune cell depletion and cancer associated fibroblasts and
such contributions to tumour suppression may only emerge
in homologous experimental systems [38, 39]. Here, using
genetic and pharmaceutical methods on mouse tumours in
immune proficient mice, we find that targeting MCL-1 can
have single-agent inhibitory effect on mammary tumour
growth of established mammary tumours. Preclinical stu-
dies demonstrating the therapeutic effect of targeting MCL-
1 in haematopoietic tumours have supported the clinical
application of MCL-1-specific BH3-mimetics: genetic
deletion of Mcl1 potently restricts tumour expansion and
enhances survival in mouse models of AML, B-cell lym-
phoma and T-cell lymphoma [40–42]. The utility of tar-
geting MCL-1 alone in solid tumours was recently
demonstrated in lung adenocarcinoma where deletion of
Mcl1 restricted tumour development and treatment with
S63845 shown to delay tumour progression in vivo [43].
Together with the present study, this validates the further
investigation of drugs targeting MCL-1 in solid tumours.
In vivo dosing of S63845 at 25 mg/kg, unlike complete
Mcl1 deletion, is well tolerated by normal tissues and our
study suggests a therapeutic window for efficacy of MCL-1
inhibitors in the clinic. In line with this, acute induction of
whole body Mcl1 haploid loss restrained the growth of
established mammary tumours and extended survival. Fur-
thermore, homozygous loss of Mcl1, specifically in the
tumour epithelium, provoked tumour regression and
allowed long-term tumour-free survival. It is worth noting
that the context in which we find single-agent effect of
S63845 in vivo has both an intact immune system and
utilised higher dosing of S63845 (twice weekly 25 mg/kg v
once weekly 25 mg/kg) when compared to related xenograft
studies that saw no effect of S63845 alone but pronounced
effects upon combination with docetaxel, trastuzumab or
Fig. 5 MCL-1 dependence requires BAX/BAK. A Tumoursphere
assay with indicated CRISPR/Cas9-modified MDA-MB-231 cell lines,
1 µM S63845 was added at time of plating and spheres were counted at
day 7. Points represent independent experiments expressed as %
tumoursphere formation relative to untreated BAX/BAK-deficient
control. Bars represent mean ± SD of three biological replicates. One-
way ANOVA analysis with Tukey’s correction for multiple compar-
isons. *P < 0.05, ***P < 0.001, n.s. not significant. B Correlation of
MCL1 expression with, SNAI2, VIM, CDH3, CD44 and ALDH1A1
across TCGA breast cancers (979 tumours [52]). *Pearson correlation
P < 0.05. ER-negative status indicated by black bar in top row.
C Comparison of VIM, SNAI2, CDH3 and ALDH1A1 expression in
low MCL1 (lower quartile) and high MCL1 (upper quartile) with ER
status indicated (red dots for ER-negative, blue dots for ER-positive
tumours) TCGA dataset as in B.
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olaparib [18, 19]. We did not see this combination effect in
an MMTV-PyMT allograft mouse model with once weekly
S63845 and docetaxel. Given the lower potency of S63845
for mouse versus human MCL-1 it may be possible that the
therapeutic index is underestimated in this context [17].
Therefore, the tumour suppressive effects of S63845
observed here could be due to increased frequency of dos-
ing and/or a combination of tumour cell and micro-
environment effects, and future studies will address the
contribution of these factors [39]. It is also possible that
whilst non-canonical functions of MCL-1 are not critical in
the MMTV-PyMT model, these roles are required in the
xenograft models tested previously.
In contrast to its critical role in MMTV-PyMT tumour
growth in vivo, we were intrigued by the dispensability of
Mcl1 for tumour cell line growth in 2D monolayers in vitro
where cell viability was jointly maintained by MCL-1 and
BCL-XL. As a role for MCL-1 has been suggested in breast
cancer stem cells we investigated growth in tumourspheres,
known to measure breast cancer stem cell activity. Despite
indifference to loss or inhibition of MCL-1 in 2D culture, the
impact of targeting MCL-1 in a tumoursphere assay was
dramatic that suggests that the biological relevance of tar-
geting MCL-1 in vivo may be underestimated by interpreta-
tion of human breast cancer cell line 2D culture [9, 12, 34].
The impact of acute homozygous Mcl1 deletion in fully
developed mammary tumours was notable with regression
occurring in almost all mice and long-term tumour-free
survival achieved in 4/9 cases. Intriguingly, we found that
tumour regression was more penetrant with genetic deletion
of MCL-1 rather than pharmaceutical inhibition. This could
indicate a non-apoptotic function of MCL-1 that is not
inhibited using BH3-mimetic drugs such as increased
mitochondrial respiration by an inner-membrane localised
form of MCL-1 [13, 21]. We therefore investigated the
ability of MCL-1 deletion to suppress MMTV-PyMT tumour
growth when the downstream apoptotic effectors BAX/
BAK were reduced. In this context there was no effect of
MCL-1 loss on tumour growth indicating that the require-
ment for MCL-1 in sustained tumour growth is due to its
known anti-apoptotic function within the BCL-2 family.
This is supported by tumoursphere assays, indicative of
breast cancer stemness, where using either human or mouse
tumour cells we found that MCL-1 inhibition with BH3-
mimetic drugs completely recapitulated the effect of MCL-1
deletion. Furthermore, reduction in BAX/BAK ablated the
negative impact of both genetic and pharmaceutical target-
ing of MCL-1 in breast cancer stem cells. Together these
data reveal that the pro-tumour role of MCL-1 in established
breast cancer is predominantly due to its function in apop-
tosis regulation within the BCL-2 family. Whilst other non-
apoptotic roles of MCL-1 could still be important in breast
cancer, its function within the BCL-2 family is crucial and
can be targeted by MCL-1-specific BH3-mimetic drugs in
development for clinical use. Breast cancer stem cells are
known to be responsible for recurrence and resistance to
therapy; therefore, the requirement for MCL-1 in breast
cancer stem cell activity, the regression of established
tumours upon loss of MCL-1 and the association between
high MCL1 and stemness markers across a range of breast
cancer patients indicate that targeting MCL-1 could be
harnessed to improve breast cancer outcome.
Materials and methods
Mice and in vivo treatments
Animals were housed in a barriered facility proactive in
environmental enrichment. All work was carried out in line
with the Animals (Scientific Procedures) Act 1986 and the
EU Directive 2010 and was sanctioned by the local ethical
review process (University of Glasgow). RosaCRE-ERT2,
MMTV-PyMT, Mcl1tm3Sjk (Mcl1fl/fl) (The Jackson
Laboratory, ME, USA), and ROSA-tdRFP mice (acquired
from the European Mouse Mutant Archive) and have all
been described previously [44–47]. All mice had been
backcrossed >10 generations FVB/N and all controls were
littermates. Mice were monitored two to three times per
week for tumour development. Tumour growth was mon-
itored by calliper measurement three times per week, by
staff blinded to outcome, and volume calculated using the
equation ([length × width2]/2). Clinical endpoint was 15 mm
diameter, at endpoint, mice were euthanized and tumours
and lungs weighed. For orthologous tumour fragment
transplant experiments single tumours were harvested from
GEMM, washed in PBS and chopped by scalpel into 2 mm
fragments immediately prior to transplantation into the
fourth mammary fat pad of 7- to 10-week-old female FVB/
N recipients (Charles River, UK). For orthologous trans-
plantation of cell lines, 0.5 million cells in 50 µl 1:1 PBS:
matrigel mix were transplanted into the fourth mammary fat
pad of 7- to 10-week-old female FVB/N recipients (Charles
River, UK). In vivo induction of CRE-ERT2 was achieved
with tamoxifen (Sigma) 10 mg/ml stock in 200 µl sunflower
seed oil by IP injection for 4 consecutive days. For in vivo
dosing, S63845 (Active Biochem) was prepared as descri-
bed [48] in 2% vitamin E/d-α-tocopheryl polyethylene
glycol 1000 succinate (Sigma) immediately prior to IV
administration by tail vein injection at 25 mg/kg and doc-
etaxel (Merck) was dissolved in PBS and administered by
intraperitoneal injection at 7.5 mg/kg. Mice were allocated
to treatment arms when tumour diameter reached ~5 mm
and distributed into treatment arms to match mean tumour
volume in a non-random manner. Sample sizes were based
on our previous experience with these models.
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Cell lines and in vitro assays
MDA-MB-231 cells used in this study are the MDA-MB-
231-luc-D3H2LN line (Covance), cell lines were authenti-
cated and confirmed negative for mycoplasma by the Mole-
cular and Advanced Technologies service at the Cancer
Research UK Beatson Institute. CRISPR/Cas9 gene editing
was achieved using LentiCRISPRv2 backbone (Addgene
#52961) with guide sequences: murine BAX: 5′-CAACTT
CAACTGGGGCCGCG-3′ and BAK: 5′-GCGCTACGAC
ACAGAGTTCC-3′; human BAX: 5′-AGTAGAAAAGGG
CGACAACC-3′, BAK: 5′-GCCATGCTGGTAGACGTG
TA-3′ and MCL1: 5’-GTATCACAGACGTTCTCGTA-3’.
Lentiviral production, cell infection and selection were per-
formed as previously described [49]. Cell lines were not
cloned and pooled populations used in all experiments. For
dual targeting of Bax/Bak in murine cells viral supernatant
from LentiCRISPRv2_puro_ Bak was applied to target cells
at 46 and 70 h post transfection being sequentially replaced
with viral supernatant from LentiCRISPRv2_blasti_ Bax at
56 and 80 h post transfection. Co-selection with 1 µg/ml
puromycin and 10 µg/ml blasticidine commenced at 94 h with
selection media being replaced every 2–3 days for 1 week
until all cells in uninfected control plates (puromycin, blas-
ticidine and puromycin + blasticidine conditions) had died.
For triple targeting of MCL1/BAX/BAK in human cells,
blasticidine encoding vectors for BAX/BAK were used as
described above to first generate BAX/BAK knockout
line. The procedure was then repeated with Lenti-
CRISPRv2_puro_ MCL1 to derive MCL1/ BAX/BAK triple
targeted lines. Empty vector LentiCRISPRv2_blasti_ and
LentiCRISPRv2_puro were used for control lines. All
experiments were performed using <20 passage cells. For
MMTV-PyMT cell line derivation, tumours were excised,
washed in PBS, then finely chopped by scalpel prior to
washing and seeding in media comprised of DMEM, 10%
FBS, 2 µM L-glutamine, 50 U/ml penicillin, 50 µg/ml strep-
tomycin (all Life Technologies), 5 µg/ml insulin (Life Tech-
nologies), 10 ng/ml EGF (Sigma) and 10 ng/ml cholera toxin.
Primary tumour cells were considered cell lines following
five successive passages as monolayers. In vitro induction of
CRE-ERT2 was achieved with 100 nM 4-hydroxytamoxifen
treatment prior to cell seeding for each experiment. YEJ2.1g-
iRFP cells are an FVB MMTV-PyMT cell line that has been
transduced with pBABE_iRFP_IRES_puro [50].
For tumoursphere assay single-cell suspension was prepared
and 1000 cells plated per well in ultra-low attachment 24 well
plates (Corning) in DMEM, 2 µM L-glutamine, 50 U/ml
penicillin, 50 µg/ml streptomycin, 1X B27 (all Gibco, UK),
20 ng/ml EGF, 20 ng/ml FGF2 and 4 µg/ml Heparin (all
Sigma) and tumourspheres >100 μm counted 7 days later. For
viability assays 15,000 cells/well were seeded in 24 well plates
and the following day the indicated treatments were added
along with SYTOX Green (Invitrogen, UK) and imaged by
Incucyte FLR (Essen Bioscience, UK). CD at 24 h post
treatment was calculated using the equation CDtreatment/
CDbasal where CDtreatment is SYTOX Green cells/cell con-
fluence following 24 h treatment and CDbasal is SYTOX
Green cells/cell confluence in control samples at 0 h. BH3-
mimetics for in vitro experiments were ABT737, ABT199,
WEHI539, A1210477 and S63845 (all ApexBio, UK). In vitro
cell lysates for western blot were prepared in RIPA buffer with
HALT Protease Inhibitor Cocktail (both Thermo Scientific,
UK) and tumour lysates prepared from excised tumour frag-
ments in the same buffer using a Precellys homogeniser
according to manufacturer’s instructions (Bertin, France).
Proteins were resolved by western blot on NuPage Bis-Tris
4–12% gradient gels (Invitrogen, UK) and transferred to
nitrocellulose membranes (Amersham, UK). Blots were pro-
bed with antibodies to MCL-1 (94296), BCL-XL (2762), BAX
(2772), BAK (12105) α-TUBULIN (2125) (all Cell Signaling,
UK) and β-ACTIN (A4700) (Sigma, UK). Secondary anti-
bodies were IRDye 800CW Donkey Anti-Rabbit IgG or
IRDye 680RD Donkey Anti-Mouse IgG (Li-cor) and visua-
lised using a Li-cor Odyssey CLx. For immunohistochemistry
antibodies to BAX (14796) and MCL-1 (94296) (Cell Sig-
naling, UK) were used with Vectastain ABC (Vector
Laboratories) used in conjunction with MCL-1 staining.
Gene expression analysis
Levels of MCL1 and a range of marker genes were assessed
in publicly available gene expression datasets. Data for
METABRIC [51] and TCGA [52] were downloaded from
c-Bioportal, data from the SCAN-B [53] study were
extracted from NCBI GEO using accession GSE96058 and
the Cb17 dataset was generated as a compendium of 2999
breast tumours from 17 Affymetrix studies integrated with
batch correction as described previously [54].
Statistical analysis
Sample size (n) is indicated in the figure legends. Statistical
significance between two experimental groups was calcu-
lated by unpaired t test, two-tailed and multiple experimental
groups by one-way ANOVA with Tukey’s correction for
multiple comparisons using GraphPad Prism version 6.0c
(GraphPad Software, CA, USA). Kaplan–Meier survival
curves of tumour-related survival were also plotted using
GraphPad Prism version 6.0c and Mantel–Cox (Log-rank).
Centre values on graphs are mean or median values and
error bars are standard deviation or standard error of the
mean as detailed for each graph in the figure legend.
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